Background: Multiple studies have indicated that specific COX-2 inhibitors may prevent
CRC. However, the long-term use of COX-2 inhibitors is not toxicity-free and may be limited …

Five experimental models were developed in different groups of Wistar rats (N= 15) to study
selective COX-2-inhibitor NSAIDs such as celecoxib and rofecoxib, as follows:(1) dose …

Conclusion Dose-dependent administration of celecoxib and rofecoxib as COX-2 inhibitors
and non-COX-1 inhibitors, respectively, did not produce toxic injuries on healthy …

The pharmacological profile of celecoxib (CAS 169590-42-5, SC-58635), a specific
cyclooxygenase-2 (COX-2) inhibitor, was investigated. Celecoxib inhibited COX-2-mediated …

Celecoxib, a COX-2 (cyclooxygenase-2)-selective inhibitor (coxib), is the only NSAID (non-
steroidal anti-inflammatory drug) that has been approved for adjuvant treatment of patients …

A simple reversed phase high-performance liquid chromatography (HPLC) method was
developed for determination of celecoxib levels in human plasma. The procedure involves …

This is a comment on" Cardiovascular risk associated with celecoxib in a clinical trial for
colorectal adenoma prevention." N Engl J Med. 2005 Mar 17; 352 (11): 1071-80. This is a …

Background: Celecoxib, a nonsteroidal antiinflammatory drug exhibits its antiinflammatory
effect by selective inhibition of cyclooxygenase-2 (COX-2) enzyme. Its efficacy has been …

Reason for posting: Coxibs, the class of NSAIDs that selectively inhibit cyclooxygenase 2
(COX-2), were designed to reduce joint pain and inflammation without causing the gastric …

Purpose. To determine the bioavailability and pharmacokinetic profile of lumiracoxib from
different sites in the gastrointestinal tract. Methods. Subjects (11 healthy adult males) were …